Sarepta Bets On GenEdit's Nanoparticles' In $57M Gene Editing Partnership

Sarepta Therapeutics Inc SRPT will pay GenEdit up to $57 million in the near term for access to the biotech's non-viral delivery platform for gene-editing therapies. 

• Sarepta will combine its gene-editing technology with GenEdit's NanoGalaxy platform to target up to four neuromuscular indications selected by Sarepta. 
• The tie-up comes after Sarepta dumped a gene therapy for a neurodegenerative disorder in partnership with Lysogene a few weeks ago. 
• Sarepta is attempting to add to its gene-editing pipeline through collaboration with GenEdit.
• Initial in vivo results have demonstrated the potential of GenEdit's polymer nanoparticles to deliver therapeutic cargo to specific muscle tissue for targeted, non-viral systemic delivery of genetic medicines. 
• The research collaboration and option agreement commenced in December 2020.
• GenEdit is also eligible for milestone payments and tiered royalties ranging from upper-single to low-double digits on future product sales. 
• Additional financial details were not disclosed.
• Price Action: SRPT shares are trading 1.73% higher at $72.81 during the market session on the last check Tuesday.